Shanghai Chest Hospital, Jiao Tong University, Shanghai, China
Dr. Shun Lu received his M.D from Shanghai Medical University, Shanghai, China in 1988, and also received his Ph.D from Second Military Medical University, Shanghai, China in 2006. Dr. Lu completed his Fellowship of Clinical Oncology in Tel Viv University, Israel 1996-1997. Further Dr. Lu received the position of Visiting Professor in the Department of Thoracic/Head and Neck Medical oncology at the University of Texas MD Anderson Cancer in Houston, Texas, USA from 2004-2005.
More than 200 peer reviewed papers were published in several journals such as: PNAS，Chest, Oncotarget, Journal of Thoracic Oncology, Lung Cancer, Plos One, Mutagenesis, etc. The total IF is 241.8
Dr. Shun Lu received several Chinese National Grant and Funding including: National Program on Key Basic Research Project of China 2016; National Natural Science Foundation of China 2016; Chinese National Science and Technology Promotion Co-operation project 2012; National High-tech R&D Program of China (863 Program) 2012 and 2008; Chinese National Science and Technology Promotion Project 2007, et al.
Dr. Lu is a committee member of numerous associations and societies including Member of ASCO International Affairs Committee (IAC) and MCMC Working Group. He is the member of IASLC membership committee, the associate editor of Journal of Thoracic Oncology and the editorial board member of the Oncologist. Dr. Lu also holds member of Expert Panel State Food and Drug Administration (China), Commissioner of Oncology Society Chinese Medical Association, Selected Director of Chinese Lung Cancer Study Association, Standing director & Deputy Secretary of Chinese Society of Clinical Oncology, Deputy director of the CSCO Committee on tumor associated anemia, Deputy director of the CSCO brain cancer expert committee, and Director of Oncology Society Chinese Medical Association Shanghai Branch. Dr. Lu is also the recipient of several awards including “Shanghai medical science Award” in 2013, “the New Medical Star in Shanghai” in 2002 and in 2004.
Dr. Lu studies novel targeted agents, immunotherapy drugs and has expertise in lung and other thoracic tumor. He also severs as the P.I or CO-P.I of more 10 international clinical trials.